Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Maximizing clozapine therapy: managing side effects

J A Lieberman1

  • 1Department of Psychiatry, University of North Carolina School of Medicine, Chapel Hill 27599-7160, USA.

The Journal of Clinical Psychiatry
|April 16, 1998
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Hippocampal dysfunction in the pathophysiology of schizophrenia: a selective review and hypothesis for early detection and intervention.

Molecular psychiatry·2018
Same author

Baseline demographics, clinical features and predictors of conversion among 200 individuals in a longitudinal prospective psychosis-risk cohort.

Psychological medicine·2017
Same author

Probable metronidazole induced serum sickness-like reaction in a paediatric patient.

Journal of clinical pharmacy and therapeutics·2016
Same author

The role of the ITIH3 rs2535629 variant in antipsychotic response.

Schizophrenia research·2016
Same author

Genome-wide association study on antipsychotic-induced weight gain in the CATIE sample.

The pharmacogenomics journal·2015
Same author

Methylenetetrahydrofolate reductase gene variants and antipsychotic-induced weight gain and metabolic disturbances.

Journal of psychiatric research·2014
Same journal

Major Depressive Disorder and PTSD Treatment Outcome in Interpersonal Psychotherapy and Prolonged Exposure.

The Journal of clinical psychiatry·2026
Same journal

Psychiatrists and Medical Aid in Dying: Entering Uncharted Waters.

The Journal of clinical psychiatry·2026
Same journal

Mind and Metabolism in Crisis: US Mortality Involving Obesity and Psychiatric Disorders-Trends, Disparities, and ARIMA Projections.

The Journal of clinical psychiatry·2026
Same journal

Generative AI for the Clinical Psychopharmacologist: Is It Ready for Prime Time?

The Journal of clinical psychiatry·2026
Same journal

Posttrauma Benzodiazepine Use and Subsequent PTSD: A Population-Wide Analysis Following Extreme Traumatic Exposure.

The Journal of clinical psychiatry·2026
Same journal

The Challenges of PTSD Prevention: Placing Benzodiazepine Use in Context.

The Journal of clinical psychiatry·2026
See all related articles

Clozapine is an effective antipsychotic for treatment-resistant schizophrenia, with manageable side effects. Mandatory monitoring significantly reduces risks like agranulocytosis, making its benefits outweigh potential dangers.

Area of Science:

  • Psychiatry
  • Pharmacology

Background:

  • Clozapine, introduced in 1990, is the sole antipsychotic proven effective for treatment-resistant schizophrenia.
  • Underutilization may stem from unfamiliarity with managing its side effects compared to older neuroleptics.

Purpose of the Study:

  • To highlight the benefits of clozapine therapy.
  • To address concerns regarding clozapine's side effects, particularly agranulocytosis.
  • To emphasize the importance of proper side effect management for maximizing treatment efficacy.

Main Methods:

  • Review of clozapine's efficacy and side effect profile.
  • Analysis of data from the Clozaril National Registry regarding agranulocytosis incidence.
  • Discussion of side effect management strategies, including dose adjustment and potential cytokine augmentation therapy.

Related Experiment Videos

Main Results:

  • Clozapine is uniquely effective for treatment-resistant schizophrenia.
  • Most clozapine side effects are benign and manageable.
  • Mandatory blood monitoring has drastically reduced agranulocytosis incidence (0.38%) and prevented fatalities.

Conclusions:

  • The benefits of clozapine treatment significantly outweigh its risks.
  • Effective management of side effects is crucial for successful clozapine therapy.
  • Ongoing research into cytokine augmentation may further mitigate blood dyscrasias.